Venture Partner
Adam Simpson is a Venture Partner at Frazier Life Sciences, where he is focused on company creation opportunities. Prior to Frazier, he served as co-founder, Chief Executive Officer and Board member at Icosavax (Nasdaq: ICVX), a company leveraging its virus-like particle platform to develop vaccines for respiratory diseases. He built a team that brought multiple product candidates into the clinic, including advancing Icosavax’s RSV/hMPV combination vaccine through Phase 3 readiness, and led the company through its IPO and subsequent acquisition by AstraZeneca. Prior to Icosavax, Adam served as the Chief Executive Officer and Board member at PvP Biologics, a company developing an oral enzyme to treat celiac disease. Adam led the company from founding through its acquisition by Takeda. Previously, Adam served as co-founder and Chief Business Officer of Meritage Pharma from inception until its sale to Shire, leading to the first FDA-approved oral product to treat eosinophilic esophagitis (Eohilia).